NOTICE -- Login operations are currently offline due to an unscheduled disruption. We are waiting for LDAP services to be re-instated. We apologize for the inconvenience - June 24, 2021
Pierre Massion
Faculty Member
Last active: 1/11/2018

The state of molecular biomarkers for the early detection of lung cancer.

Hassanein M, Callison JC, Callaway-Lane C, Aldrich MC, Grogan EL, Massion PP
Cancer Prev Res (Phila). 2012 5 (8): 992-1006

PMID: 22689914 · PMCID: PMC3723112 · DOI:10.1158/1940-6207.CAPR-11-0441

Using biomarkers to select the most at-risk population, to detect the disease while measurable and yet not clinically apparent has been the goal of many investigations. Recent advances in molecular strategies and analytic platforms, including genomics, epigenomics, proteomics, and metabolomics, have identified increasing numbers of potential biomarkers in the blood, urine, exhaled breath condensate, bronchial specimens, saliva, and sputum, but none have yet moved to the clinical setting. Therefore, there is a recognized gap between the promise and the product delivery in the cancer biomarker field. In this review, we define clinical contexts where risk and diagnostic biomarkers may have use in the management of lung cancer, identify the most relevant candidate biomarkers of early detection, provide their state of development, and finally discuss critical aspects of study design in molecular biomarkers for early detection of lung cancer.

MeSH Terms (4)

Biomarkers, Tumor Early Diagnosis Humans Lung Neoplasms

Connections (4)

This publication is referenced by other Labnodes entities: